First International Symposium on Merkel Cell Carcinoma
Monday and Tuesday, October 21-22, 2019
Moffitt Cancer Center
Stabile Research Building
12902 USF Magnolia Drive
Tampa, FL 33612-9416
The International Symposium on Merkel Cell Carcinoma is a first-of-its kind educational program of thought leaders and active investigators in Merkel cell carcinoma (MCC) brought together for the purpose of promoting scientific discourse and collaboration towards the goal of improved understanding of MCC biology, pathogenesis, and therapy.
The areas of focus will span the entire range of basic science to translational studies to clinical trials. The format will include a several sessions with talks and abstract presentations emphasizing new, unpublished work throughout the 2-day symposium. The areas of focus will span the entire range of basic science to translational studies to clinical trials. The format will include a plenary session with presentations from leaders in the field. The majority of the talks will emphasize new, unpublished work throughout the 2-day symposium. Roundtable / debate-style discussions will be centered on pressing questions in the field including how best to address immunotherapy resistance, the relevance of viral integration and transcription in driving clinical outcomes, and the future of molecularly-targeted and orthogonal immunotherapeutic approaches.
We would like to especially highlight the contributions of scientific and clinical trainees so as to inspire the next generation of investigators to continue work in this field. Part of this goal will be accomplished by including presentations and travel grants for promising trainees studying MCC.
Confirmed attendees include: Paul Nghiem, MD, PhD (University of Washington); James DeCaprio, MD (Dana Farber Cancer Institute); Jürgen Becker, MD (Essen); Evan Wuthrick, MD (Moffitt Cancer Center); Jonathan Zager, MD (Moffitt Cancer Center); Sandra D’Angelo, MD (Memorial Sloan Kettering); Janis Taube, MD (Johns Hopkins); David Miller, MD, PhD (Massachusetts General Hospital); Evan Lipson, MD (Johns Hopkins); Isaac Brownell, MD ; Paul Harms, MD (University of Michigan); Keith Delman, MD (Emory University);
This program is designed for investigators involved across the entire spectrum of Merkel cell carcinoma research. This includes surgeons, dermatologists, dermatopathologists, radiation oncologists, and other healthcare professionals, as well as translational and basic scientists interested in or working on Merkel cell carcinoma.
Conference Contact: Gina.Woodward@Moffitt.org